




RealRate

# PHARMACEUTICAL 2023

## International Stem Cell CORP Rank 310 of 446





RealRate

# PHARMACEUTICAL 2023

## International Stem Cell CORP Rank 310 of 446



The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of International Stem Cell CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 123% points. The greatest weakness of International Stem Cell CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is -14%, being 57% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	2,963
Cost of Goods Sold	3,269
Intangible Assets	878
Liabilities, Current	4,635
Liabilities, Non-Current	720
Other Assets	1,046
Other Compr. Net Income	0
Other Expenses	1,245
Other Liabilities	0
Other Net Income	-148
Other Revenues	8,180
Property and Equipment	248
Research and Development	492
Selling, General and Administrative Expense	3,357

Output Variable	Value in 1000 USD
Assets	5,135
Liabilities	5,355
Expenses	8,363
Revenues	8,180
Stockholders Equity	-220
Net Income	-331
Comprehensive Net Income	-331
Economic Capital Ratio	-14%